| 1 |
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011，183(6): 788-824.
|
| 2 |
Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline[J]. Am J Respir Crit Care Med, 2015, 192(2): e3-e19.
|
| 3 |
Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 1998, 157(1): 199-203.
|
| 4 |
Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia[J]. Eur Respir J, 2002, 19(2): 275-283.
|
| 5 |
King TJ, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis：relationship between histopathologic features and mortality[J]. Am J Respir Crit Care Med, 2001, 164(6): 1025-1032.
|
| 6 |
Rudd RM, Prescott RJ, Chalmers JC, et al. British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival[J]. Thorax, 2007, 62(1): 62-66.
|
| 7 |
中华医学会呼吸病学分会间质性肺病学组，中国医师协会呼吸医师分会间质性肺疾病工作委员会. 特发性肺纤维化急性加重诊断和治疗中国专家共识[J]. 中华医学杂志，2019, 99(26): 2014-2023.
|
| 8 |
任成山，钱桂生. 特发性间质性肺炎的现代概念及研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2010, 10(4): 276-284.
|
| 9 |
邱 静，孙 建，李万成. 特发性肺纤维化中TGF-β1诱导上皮细胞间质转化作用机制研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(2): 212-214.
|
| 10 |
Ryerson CJ, Cottin V, Brown KK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm [J]. Eur Respir J, 2015, 46(2): 512-520.
|
| 11 |
Atkins CP, Loke YK, Wilson AM. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials[J]. Respir Med, 2014, 108(2): 376-387.
|
| 12 |
Collard HR, Yow E, Richeldi L, et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials[J]. Respir Res, 2013, 14(1): 73.
|
| 13 |
Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome[J]. Eur Respir J, 2011, 37(2): 356-363.
|
| 14 |
Simon-Blancal V, Freynet O, Nunes H, et al. Acute exacerbation of idiopathic pulmonary fibrosis: Outcome and prognostic factors[J]. Respir, 2012, 83(1): 28-35.
|
| 15 |
Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences[J]. Am J Respir Crit Care Med, 2014, 190(7)：773-779.
|
| 16 |
Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: A population-based study[J]. Chest, 2010, 137(1): 129-137.
|
| 17 |
Fernández Fabrellas E, Peris Sánchez R, Sabater Abad C, et al. Prognosis and follow-up of idiopathic pulmonary fibrosis[J]. Med Sci (Basel), 2018, 6(2): 51.
|
| 18 |
Invernizzi R, Molyneaux PL. The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis[J]. Eur Respir Rev, 2019, 28(152): 190045.
|
| 19 |
Weng D, Chen XQ, Qiu H, et al. The role of infection in acute exacerbation of idiopathic pulmonary fibrosis[J]. Med Inflamm, 2019, 2019: 5160694.
|
| 20 |
Johannson K, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: A proposal[J]. Curr Respir Care Rep, 2013, 2(4): 10.
|
| 21 |
魏丽娟，庄蝶微，崔 娜，等. 特发性肺纤维化生存影响因素分析[J]. 中日友好医院学报，2015, 29(5): 297-298.
|
| 22 |
秦文婧，梁 宇，单远莹，等. 影响特发性肺纤维化预后的相关因素分析[J]. 中国现代医生，2016, 54(02): 33-35.
|
| 23 |
Kang HS, Cho KW, Kwon SS, et al. Prognostic significance of Glasgow prognostic score in patients with acute exacerbation of idiopathic pulmonary fibrosis[J]. Respir, 2018, 23(2): 206-212.
|
| 24 |
冷 冬，李桂芹，王 颖，等. 肺纤维化风险预测的临床生物化学模型[J]. 首都医科大学学报，2019, 40(6): 875-880.
|
| 25 |
Ishikawa G, Acquah SO, Salvatore M, et al. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease[J]. Respir Med, 2017, 128: 78-84.
|
| 26 |
李 燕，苗立云，姜涵毅，等. 特发性肺纤维化预后相关因素的回顾性研究[J]. 中国呼吸与危重监护杂志，2012, 11(3): 257-261.
|
| 27 |
Isshiki T, Sakamoto S, Kinoshita A, et al. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study [J]. Respir, 2015, 89(3): 201-207.
|
| 28 |
Hachisu Y, Murata K, Takei K, et al. Possible serological markers to predict mortality in acute exacerbation of idiopathic pulmonary fibrosis[J]. Med (Kaunas), 2019, 55(5): 132-143.
|